Entera Bio Ltd. Long Term Debt (Total)

Long Term Debt (Total) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.


Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending June 29, 2020 was $81 Thousand (a -37.69% decrease compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) decreased by -53.18%
  • Annual Long Term Debt (Total) for 2019 was $122 Thousand (a -96.87% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of Entera Bio Ltd.

Most recent Long Term Debt (Total)of ENTX including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of Entera Bio Ltd.

Entera Bio Ltd. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.08 $0.13
2019 $0.12 $0.17 $0.19 $0.22 $0.12
2017 $3.89 $3.89

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.